Business news for the stock market
Leverkusen, Germany (pta006/29.05.2023/12:05) - Biofrontera AG (Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, will be releasing its financial results for the first quarter 2023 on Wednesday, May 31, 2023.
The Chief Financial Officer of Biofrontera AG will provide information on the key developments in the reporting period in a conference call on Wednesday, May 31, 2023.
The conference call for shareholders and interested investors will start at 2:00 p.m. and will be held in English.
Conference Call - ENGLISH
May 31, 2023, 2:00 p.m. CEST.
PARTICIPANT INTERNATIONAL DIAL IN: +1-412-858-5202
Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Leverkusen-based company develops and markets innovative products for the treatment, protection and care of the skin. Its key products include Ameluz®, a prescription drug for the treatment of non-melanoma skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the USA since May 2016. In Europe, the company also markets the Belixos® dermocosmetic series, a specialty care product for damaged skin. Biofrontera is one of a few German pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 and is listed on the Frankfurt Stock Exchange (Prime Standard). www.biofrontera.com
emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate